PFIZER RECEIVES ZOLOFT OCD INDICATION WITHOUT DOSE-RESPONSE RELATIONSHIP; FIRM HAS SUBMITTED PROPOSED CORRECTIVE PLAN IN RESPONSE TO FDA WARNING LETTER
Pfizer's fourteen-month wait for final FDA approval for an obsessive-compulsive disorder indication for the antidepressant Zoloft (sertraline) appears in part to be attributable to the company's persistent, but ultimately unsuccessful, pursuit of labeling language to indicate a firm dose-response relationship for the drug.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth